晨光生物
(300138)
| 流通市值：44.33亿 | | | 总市值：53.77亿 |
| 流通股本：3.98亿 | | | 总股本：4.83亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,159,134,012.82 | 1,628,953,634.09 | 6,559,043,728.38 | 5,047,254,465.57 |
| 营业收入 | 3,159,134,012.82 | 1,628,953,634.09 | 6,559,043,728.38 | 5,047,254,465.57 |
| 二、营业总成本 | 2,968,152,280.45 | 1,521,636,644.31 | 6,178,716,674.03 | 4,718,060,635.45 |
| 营业成本 | 2,733,836,302.63 | 1,406,101,111.98 | 5,699,727,242.87 | 4,316,379,997.65 |
| 税金及附加 | 11,150,980.22 | 5,662,182.99 | 24,397,878.8 | 19,490,379.39 |
| 销售费用 | 26,875,304.58 | 14,497,957.97 | 59,775,632.57 | 45,953,832.36 |
| 管理费用 | 73,686,010.16 | 35,107,909.57 | 170,757,767.09 | 136,247,370.54 |
| 研发费用 | 69,436,945.19 | 33,289,753.14 | 166,241,135.28 | 159,491,892.98 |
| 财务费用 | 53,166,737.67 | 26,977,728.66 | 57,817,017.42 | 40,497,162.53 |
| 其中:利息费用 | 60,167,537.11 | 28,976,190.97 | 90,825,719.52 | 70,036,521.24 |
| 其中:利息收入 | 18,223,894.48 | 7,702,249.6 | 38,452,235.58 | 31,933,849.65 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -3,955,949.53 | -5,998,869.38 | 9,273,528.3 | 4,167,742.31 |
| 加:投资收益 | 8,382,074.23 | 4,534,042.4 | 46,353,968.87 | 31,939,889.39 |
| 资产处置收益 | 29,000.02 | - | 1,457,326.99 | 3,782,019.01 |
| 资产减值损失(新) | -6,086,379.22 | 100,581.94 | -39,220,328.62 | -24,896,091.54 |
| 信用减值损失(新) | -465,519.67 | 368,660.54 | -3,514,372.5 | 1,086,476.53 |
| 其他收益 | 21,982,082.09 | 7,337,168.02 | 41,682,418.11 | 23,421,591.34 |
| 四、营业利润 | 210,867,040.29 | 113,658,573.3 | 436,359,595.5 | 368,695,457.16 |
| 加:营业外收入 | 3,315,877.32 | 519,202.74 | 8,206,654.46 | 5,532,865.87 |
| 减:营业外支出 | 1,983,343.55 | 296,717.79 | 6,696,262.5 | 3,881,742.54 |
| 五、利润总额 | 212,199,574.06 | 113,881,058.25 | 437,869,987.46 | 370,346,580.49 |
| 减:所得税费用 | 27,913,297.69 | 15,480,570.51 | 62,994,511.61 | 59,017,512.04 |
| 六、净利润 | 184,286,276.37 | 98,400,487.74 | 374,875,475.85 | 311,329,068.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 184,286,276.37 | 98,400,487.74 | 374,875,475.85 | 311,329,068.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 178,530,349.2 | 96,721,584.04 | 368,871,080.68 | 303,829,082.4 |
| 少数股东损益 | 5,755,927.17 | 1,678,903.7 | 6,004,395.17 | 7,499,986.05 |
| 扣除非经常损益后的净利润 | 162,790,015.98 | 95,527,641.52 | 278,932,583.15 | 255,982,097.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.37 | 0.2 | 0.76 | 0.63 |
| (二)稀释每股收益 | 0.37 | 0.2 | 0.76 | 0.63 |
| 八、其他综合收益 | -22,763,435.29 | -13,913,355.02 | -26,494,256.96 | -15,928,224.68 |
| 归属于母公司股东的其他综合收益 | -22,763,435.29 | -13,913,355.02 | -26,494,256.96 | -15,928,224.68 |
| 九、综合收益总额 | 161,522,841.08 | 84,487,132.72 | 348,381,218.89 | 295,400,843.77 |
| 归属于母公司股东的综合收益总额 | 155,766,913.91 | 82,808,229.02 | 342,376,823.72 | 287,900,857.72 |
| 归属于少数股东的综合收益总额 | 5,755,927.17 | 1,678,903.7 | 6,004,395.17 | 7,499,986.05 |
| 公告日期 | 2026-08-25 | 2026-04-25 | 2026-03-31 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |